All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for youFind out more
Bookmark this article
The AML Hub is pleased to present a visual abstract summarizing the key results from the phase III randomized placebo-controlled MORPHO trial (NCT02997202) evaluating gilteritinib as a maintenance therapy in patients with FLT3-internal tandem duplication (ITD) acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation in first remission.1
Results from the MORPHO trial were presented by Levis1 at the European Hematology Association (EHA) 2023 Hybrid Congress. The findings of this study suggest that post-allo-HSCT gilteritinib maintenance therapy could be the standard of care for patients with FLT3-ITD acute myeloid leukemia who are measurable residual disease positive pre- or post-allo-HSCT.
To download this visual abstract, click below.Download here
Gilteritinib receives positive recommendation from EMA CHMP for the treatment of FLT3-mutated AML
EMA CHMP recommends that gilteritinib is granted marketing authorization in Europe for the treatment of FLT3-mutated relapsed/refractory (R/R) acute...
EHA 2019 | Which research areas hold promise for future treatments for AML?
Isolda Fernandez discusses research areas holding promise for future treatments for acute myeloid leukemia (AML) with the AML Global Portal at EHA 2019, Amsterdam, NL.
Subscribe to get the best content related to AML delivered to your inbox